ATPases as drug targets: learning from their structure
Author:
- 1 September 2002
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 1 (9) , 665-673
Abstract
ATPases are involved in several cellular functions, and are at the origin of various human diseases. They are therefore attractive drug targets, and various ATPase inhibitors are already on the market. However, most of these drugs are active without binding directly to the nucleotide-binding site. An alternative strategy to inhibit ATPases is to design competitive ATP inhibitors. This approach, which has been used successfully to design protein-kinase inhibitors, depends on the structure of the nucleotide-binding site. This review describes the structural features of the nucleotide-binding site of various ATPases and analyses how this structural information can be exploited for drug discovery.Keywords
This publication has 87 references indexed in Scilit:
- Inhibition of Branched-Chain α-Keto Acid Dehydrogenase Kinase and Sln1 Yeast Histidine Kinase by the Antifungal Antibiotic RadicicolMolecular Pharmacology, 2002
- Structure and function of the N‐terminal 40 kDa fragment of human PMS2: a monomeric GHL ATPaseThe EMBO Journal, 2001
- Structure and mechanism of the RuvB holliday junction branch migration motorJournal of Molecular Biology, 2001
- Advances in DNA gyrase inhibitorsExpert Opinion on Investigational Drugs, 2001
- Structural Biology of Rad50 ATPaseCell, 2000
- The Protein Data BankNucleic Acids Research, 2000
- Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based ScreenScience, 1999
- DNA binding mediates conformational changes and metal ion coordination in the active site of PcrA helicase 1 1Edited by A. R. FershtJournal of Molecular Biology, 1999
- Protein Recognition of Adenylate: An Example of a Fuzzy Recognition TemplateJournal of Molecular Biology, 1996
- Chemical and biological evolution of a nucleotide-binding proteinNature, 1974